Skip to main content
. 2023 Sep 19;2023(9):CD014791. doi: 10.1002/14651858.CD014791.pub2

Summary of findings 1. Silicone hydrogel versus hydrogel soft contact lenses for differences in patient‐reported comfort and safety.

Silicone hydrogel versus hydrogel soft contact lenses for differences in patient‐reported comfort and safety
Patient or population: adults with refractive errors
Settings: community private practices or university‐affiliated eye clinics
Intervention: silicone hydrogel soft contact lenses (Balafilcon A, Comfilcon A, Delefilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Senofilcon A)
Comparison: hydrogel soft contact lenses (Etafilcon A, Nelfilcon A, Ocufilcon B)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of evidence
(GRADE)
Comments
Assumed risk
hydrogel
Corresponding risk
silicone hydrogel
Mean change in patient‐reported comfort score from baseline using CLDEQ‐8 No studies assessed this outcome.  
Mean change in patient‐reported comfort score from baseline using OSDI, at 1 month
(MD < 0 favored)
23.44 (SD 17) 22.24 (12.95 to 31.53) MD
−1.20
(−10.49 to 8.09)
47
(1 RCT)
⊕⊝⊝⊝
Very low1,2
Results reported at 3 months for this RCT were similar (MD 1.43, 95% CI −8.05 to 10.91).
Mean change in patient‐reported comfort score from baseline using VAS, at 1 week
(MD > 0 favored)
3.35 (SD 1.5) 3.9 (3.51 to 4.29) MD 0.55
(0.16 to 0.94)
240
(1 RCT)
⊕⊝⊝⊝
Very low3,4
VAS 0 to 5; 5 = excellent comfort
Proportion of participants who discontinued contact lens wear, at 1 week
(RR < 1 favored)
25 per 1000 16 (3 to 94) per 1000 RR 0.64
(0.11 to 3.74)
248
(1 RCT)
⊕⊝⊝⊝
Very low1,2
Pooled results by adding data from 4 other RCTs with follow‐up time up to 52 weeks (total n = 1273) were similar (RR 0.92, 95% CI 0.73 to 1.16).
Corneal staining scores, at 1 week
(MD < 0 favored)
0.56 (SD 0.43) 0.31 (0.20 to 0.42) MD −0.25
(−0.36 to −0.14)
243
(1 RCT)
⊕⊝⊝⊝
Very low3,4
≥ 0.5 units clinically meaningful (Dundas 2001)
NEI grading scale5
Conjunctival staining scores, at 1 month
(MD < 0 favored)
0.3 (SD 0.5) 0.5 (0.28 to 0.72) MD 0.20
(−0.02 to 0.42)
80
(1 RCT)
⊕⊝⊝⊝
Very low3,4
≥ 0.5 units clinically meaningful (Dundas 2001)
5‐point scale6
Proportion of participants with vision‐threatening adverse events
(RR < 1 favored)
4 weeks ⊕⊝⊝⊝
Very low1,2
 
5 per 1000 3 (0 to 28) per 1000 RR 0.68
(0.08 to 5.51)
368
(2 RCTs)
3 months
50 per 1000 178 (10 to 1000) per 1000 RR 3.56
(0.19 to 66.72)
90
(1 RCT)
52 weeks
271 per 1000 550 (374 to 810) per 1000 RR 2.03
(1.38 to 2.99)
815
(2 RCTs)
*The basis for the assumed risk is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI, confidence interval; CLDEQ‐8, Contact Lens Dry Eye Questionnaire‐8; MD, mean difference; NEI, National Eye Institute; OSDI, Ocular Surface Disease Index; RCT, randomized controlled trial; RR, risk ratio; SD, standard deviation; VAS, visual analog scale
GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

1Downgraded for risk of bias (−1).
2Downgraded for extreme imprecision (−2).
3Downgraded for high risk of bias (−2).
4Downgraded for imprecision (−1).
5NEI grading scale 0 to 3; 0 = normal, 1 = mild, 2 = moderate, 3 = severe; inferior region only.
65‐point scale 0 to 4; 0 = none, 4 = severe; scores were averages of quadrants.